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CASE 1 
A 45-year-old man was referred for progressive stage 
IV lung adenocarcinoma after second-line chemotherapy. He 
had an Eastern Cooperative Oncology Group performance 
status of 2 with bone pain. Chest and abdominal computed 
tomography (CT) showed a right pleural effusion with liver 
and diffuse bone metastases. Magnetic resonance imaging 
(MRI) of the brain revealed an asymptomatic left frontal 
lesion. Given the evidence of positive EML4-ALK rear-
rangement on the pleural biopsy (assessed by fluorescence in 
situ hybridization), crizotinib 250 mg twice daily was started. 
After 2 weeks, the patient’s performance status improved to 
0, with disappearance of bone pain. Six weeks after start-
ing treatment, CT demonstrated a significant shrinkage of 
all tumor sites outside the central nervous system (CNS). 
However, an MRI performed 6 and 10 weeks after the initia-
tion of crizotinib showed multiple new brain lesions and an 
increased size of the left frontal metastasis (shown in Fig. 1). 
The patient received whole-brain radiotherapy (WBRT) after 
discontinuation of crizotinib but died after 3 weeks, from pro-
gression of brain metastases.
CASE 2
A 57-year-old man with stage IV lung adenocarcinoma 
had progressive disease after three lines of treatment, including 
chemotherapy, bevacizumab, and erlotinib. Chest and abdomi-
nal CT showed pulmonary lymphangitic carcinomatosis, right 
pleural effusion, and peritoneal carcinomatosis. A brain MRI 
revealed multiple, small, diffuse asymptomatic metastases. 
Given the evidence from fluorescence in situ hybridization 
of EML4-ALK rearrangement in the initial biopsy, treatment 
was begun with crizotinib 250 mg twice daily. Four weeks 
later, chest and abdominal CT showed decreased pulmonary 
lymphangitic carcinomatosis, disappearance of the peritoneal 
effusion, and stable pleural effusion. However, the patient 
experienced progressive ataxia and MRI revealed an increase 
in the size and number of brain lesions. The patient received 
WBRT after discontinuation of crizotinib but died 9 weeks 
later from carcinomatous meningitis.
DISCUSSION
ALK-EML4 translocation is a recently discovered tyro-
sine kinase target present in 4% to 5% of non–small-cell lung 
cancers.1 Crizotinib, an inhibitor of ALK tyrosine kinase, 
often produces dramatic responses in patients with ALK rear-
rangement, with a reported overall response rate of 55% and a 
2-year overall survival of 54%.2–4
Resistance to crizotinib can occur through several 
mechanisms. These include secondary mutations in the ALK 
kinase domain, gain of ALK gene fusion copy number, and 
emergence of other oncogenic drivers.5 The brain seems to be 
a common and preferential site of relapse, probably related 
to poor penetration of crizotinib into the CNS. Shaw et al.4 
described a patient treated with crizotinib, who presented with 
progressive cerebral disease, although tumor outside the CNS 
did not progress. The concentration of crizotinib was 0.53 
µmol/liter in plasma but only 0.0014 µmol/liter in the cerebro-
spinal fluid.3 This could explain the contrast seen in our two 
cases between disease progression in the brain, and response 
or stable disease in other tumor sites.
The majority of patients included in clinical trials 
assessing crizotinib had brain metastases that were controlled 
by prior treatment. More data are needed to evaluate the activ-
ity of crizotinib on brain metastases and to determine whether 
WBRT should be given before crizotinib in cases of untreated 
CNS lesions.
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FIGURE 1.  Abdominal computed tomography (A) before and (B) after 6 weeks of crizotinib showed a substantial decrease 
in the size of all liver metastases. C, D, and E, Magnetic resonance imaging T1 gadolinium at (A) initiation of crizotinib and 
after (B ) 6 and (C)10 weeks of treatment showed an increase in size of the left frontal cerebral metastasis of 28 mm to 54 mm 
associated with the appearance of a right periventricular lesion.
